EBI-907 is a potent, orally active B-RafV600E inhibitor with promising applications in the research of melanoma and other B-RafV600E-related cancers; it demonstrates excellent antiproliferative activity against A375 and Colo-205 cells (IC50 = 13 nM and 14 nM, respectively) and induces tumor regression in a B-RafV600E-dependent Colo-205 xenograft mouse model.